ID   KTCTL-21
AC   CVCL_5868
SY   KTCTL21; RCC-AB; RCCAB
DR   ArrayExpress; E-MTAB-3610
DR   CCLE; RCCAB_KIDNEY
DR   Cell_Model_Passport; SIDM00821
DR   CLS; 300247/NA
DR   Cosmic; 1352059
DR   Cosmic; 1751970
DR   Cosmic-CLP; 1524418
DR   DepMap; ACH-002187
DR   GDSC; 1524418
DR   GEO; GSM1670360
DR   PharmacoDB; RCCAB_1287_2019
DR   Wikidata; Q54900641
RX   PubMed=8086765;
RX   PubMed=27397505;
RX   PubMed=28489074;
RX   PubMed=30894373;
WW   http://www.xlbiotec.com/product.php?productid=40243
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.07%; East Asian, North=0.03%; East Asian, South=0%; South Asian=1.41%; European, North=62.87%; European, South=35.62% (PubMed=30894373).
CC   Discontinued: CLS; 300247; true.
ST   Source(s): CLS; Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10,13
ST   D13S317: 12,13
ST   D16S539: 11
ST   D18S51: 15
ST   D21S11: 30,33.2
ST   D3S1358: 17
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   D8S1179: 12,15
ST   FGA: 22,25
ST   Penta D: 10,12
ST   Penta E: 7
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 15,19
DI   NCIt; C4033; Clear cell renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   49Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 17
//
RX   PubMed=8086765; DOI=10.1007/BF00252823;
RA   Gross A.J., Wolff M., Fandrey J., Miersch W.-D., Dieckmann K.-P.,
RA   Jelkmann W.;
RT   "Prevalence of paraneoplastic erythropoietin production by renal cell
RT   carcinomas.";
RL   Clin. Investig. 72:337-340(1994).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165-15165(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//